# EDGAR Filing Document

**Accession Number:** 0001835579
**File Stem:** 0000000000-25-005870
**Filing Date:** 2025-6
**Character Count:** 3792
**Document Hash:** 1a8aef0f1245c62a2d0822976a6c3eee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-005870.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0000000000-25-005870

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250603

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ImageneBio, Inc.
- **CENTRAL INDEX KEY:** 0001835579
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811697316
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-285881

**BUSINESS ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 857-343-8292

**MAIL ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ikena Oncology, Inc.
- **DATE OF NAME CHANGE:** 20201208
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001140361-25-009263

## Text-Extract

```

                                                             June 3, 2025

Jotin Marango, M.D., Ph.D.
Chief Financial Officer and Chief Operating Officer
Ikena Oncology, Inc.
645 Summer Street, Suite 101
Boston, MA 02210

       Re: Ikena Oncology, Inc.
           Amendment No. 4 to Registration Statement on Form S-4
           Filed May 30, 2025
           File No. 333-285881
Dear Jotin Marango M.D., Ph.D.:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Amendment No. 4 to Registration Statement on Form S-4
Questions and Answers
Q: Who will be the executive officers of the combined company immediately
following the
Merger?, page 9

1.     We note your revised disclosure indicating that the chief executive
officer and chief
       financial officer of the combined company have not been identified.
Please revise the
       response to this question to disclose why they have not been identified,
the criteria
       that will be used to appoint a new CEO and CFO, the person(s) who will
act as your
       principal executive officer and principal financial officer following
the Merger
       and the risks of operating as a public company without a permanent CEO
and/or CFO.
Management Following the Merger, page 353

2.     Prior to effectiveness, please revise this section, as well as the Q&A
on page 8, to
 June 3, 2025
Page 2

       identify each of the directors of the combined company following the
Merger,
       including the director to be jointly agreed between Ikena and Inmagene
and the
       director to be designated by Deep Track Master Fund.
       Please contact Christine Torney at 202-551-3652 or Lynn Dicker at
202-551-3616 if
you have questions regarding comments on the financial statements and related
matters. Please contact Daniel Crawford at 202-551-7767 or Alan Campbell at
202-551-4224
with any other questions.

                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences
cc:   Amanda Gill, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._